GB9709421D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
GB9709421D0
GB9709421D0 GBGB9709421.3A GB9709421A GB9709421D0 GB 9709421 D0 GB9709421 D0 GB 9709421D0 GB 9709421 A GB9709421 A GB 9709421A GB 9709421 D0 GB9709421 D0 GB 9709421D0
Authority
GB
United Kingdom
Prior art keywords
cell
targeting moiety
conjugate
mammalian host
chemical compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9709421.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Priority to GBGB9709421.3A priority Critical patent/GB9709421D0/en
Publication of GB9709421D0 publication Critical patent/GB9709421D0/en
Priority to GBGB9808146.6A priority patent/GB9808146D0/en
Priority to AU72254/98A priority patent/AU734915B2/en
Priority to CA002286875A priority patent/CA2286875A1/en
Priority to NZ500014A priority patent/NZ500014A/en
Priority to KR10-1999-7010394A priority patent/KR100508136B1/ko
Priority to PL98337007A priority patent/PL337007A1/xx
Priority to US09/423,439 priority patent/US6339070B1/en
Priority to AT98919380T priority patent/ATE412755T1/de
Priority to BR9808769-0A priority patent/BR9808769A/pt
Priority to IL13234898A priority patent/IL132348A0/xx
Priority to DE69840165T priority patent/DE69840165D1/de
Priority to CNB988049295A priority patent/CN1268743C/zh
Priority to RU99126647/13A priority patent/RU2218404C2/ru
Priority to SK1535-99A priority patent/SK153599A3/sk
Priority to EP98919380A priority patent/EP0979292B1/en
Priority to PCT/GB1998/001294 priority patent/WO1998051787A2/en
Priority to TR1999/02731T priority patent/TR199902731T2/xx
Priority to JP54889298A priority patent/JP2001526539A/ja
Priority to GB9922815A priority patent/GB2338484B/en
Priority to ES98919380T priority patent/ES2314990T3/es
Priority to HU0001931A priority patent/HUP0001931A3/hu
Priority to ZA983931A priority patent/ZA983931B/xx
Priority to MYPI98002086A priority patent/MY140975A/en
Priority to NO995475A priority patent/NO995475L/no
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y10S977/804—Containing nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Mechanical Coupling Of Light Guides (AREA)
GBGB9709421.3A 1997-05-10 1997-05-10 Chemical compounds Pending GB9709421D0 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
GBGB9709421.3A GB9709421D0 (en) 1997-05-10 1997-05-10 Chemical compounds
GBGB9808146.6A GB9808146D0 (en) 1997-05-10 1998-04-17 Chemical compounds
HU0001931A HUP0001931A3 (en) 1997-05-10 1998-05-05 Chemical compounds
CNB988049295A CN1268743C (zh) 1997-05-10 1998-05-05 编码细胞靶向部分和异源前体药物活化酶的基因构建体及其应用
RU99126647/13A RU2218404C2 (ru) 1997-05-10 1998-05-05 Совместимая двухкомпонентная система, предназначенная для применения у млекопитающего-хозяина в качестве лекарственного средства (варианты), способ доставки цитотоксического лекарства
NZ500014A NZ500014A (en) 1997-05-10 1998-05-05 Gene directed carboxypeptidase prodrug therapy using in situ antibody generation, A5B7 or 806.077, for use in cancer therapy.
KR10-1999-7010394A KR100508136B1 (ko) 1997-05-10 1998-05-05 화합물
PL98337007A PL337007A1 (en) 1997-05-10 1998-05-05 Chemical compounds
US09/423,439 US6339070B1 (en) 1997-05-10 1998-05-05 Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety
AT98919380T ATE412755T1 (de) 1997-05-10 1998-05-05 GENKONSTRUKT DAS FÜR EIN HETEROLOGES ßPRODRUGß- AKTIVIERENDES ENZYM UND FÜR EIN ZELLGERICHTES TEIL KODIERT
BR9808769-0A BR9808769A (pt) 1997-05-10 1998-05-05 Construção de gene, uso de uma construção de gene, sistema de dois componentes emparelhados, designado para o uso em um hospedeiro mamìfero, e, processo para transferência de um medicamento citotóxico para um sìtio
IL13234898A IL132348A0 (en) 1997-05-10 1998-05-05 Gene directed antibody-enzyme prodrug therapy
DE69840165T DE69840165D1 (de) 1997-05-10 1998-05-05 Genkonstrukt das für ein heterologes "prodrug"-aktivierendes enzym und für ein zellgerichtes teil kodiert
AU72254/98A AU734915B2 (en) 1997-05-10 1998-05-05 Chemical compounds
CA002286875A CA2286875A1 (en) 1997-05-10 1998-05-05 Chemical compounds
SK1535-99A SK153599A3 (en) 1997-05-10 1998-05-05 Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety
EP98919380A EP0979292B1 (en) 1997-05-10 1998-05-05 Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety
PCT/GB1998/001294 WO1998051787A2 (en) 1997-05-10 1998-05-05 Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety
TR1999/02731T TR199902731T2 (xx) 1997-05-10 1998-05-05 Kimyasal bile�ikler.
JP54889298A JP2001526539A (ja) 1997-05-10 1998-05-05 化合物
GB9922815A GB2338484B (en) 1997-05-10 1998-05-05 Medicaments comprising a nucleic acid encoding a cell targeting moiety and a prodrug activating enzyme
ES98919380T ES2314990T3 (es) 1997-05-10 1998-05-05 Construccion de gen que codifica una enzima heterologa que activa un profarmaco y un resto reconocedor de celulas.
MYPI98002086A MY140975A (en) 1997-05-10 1998-05-08 Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety
ZA983931A ZA983931B (en) 1997-05-10 1998-05-08 Chemical compounds
NO995475A NO995475L (no) 1997-05-10 1999-11-09 Kjemiske forbindelser

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9709421.3A GB9709421D0 (en) 1997-05-10 1997-05-10 Chemical compounds

Publications (1)

Publication Number Publication Date
GB9709421D0 true GB9709421D0 (en) 1997-07-02

Family

ID=10812048

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB9709421.3A Pending GB9709421D0 (en) 1997-05-10 1997-05-10 Chemical compounds
GB9922815A Expired - Fee Related GB2338484B (en) 1997-05-10 1998-05-05 Medicaments comprising a nucleic acid encoding a cell targeting moiety and a prodrug activating enzyme

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB9922815A Expired - Fee Related GB2338484B (en) 1997-05-10 1998-05-05 Medicaments comprising a nucleic acid encoding a cell targeting moiety and a prodrug activating enzyme

Country Status (23)

Country Link
US (1) US6339070B1 (enExample)
EP (1) EP0979292B1 (enExample)
JP (1) JP2001526539A (enExample)
KR (1) KR100508136B1 (enExample)
CN (1) CN1268743C (enExample)
AT (1) ATE412755T1 (enExample)
AU (1) AU734915B2 (enExample)
BR (1) BR9808769A (enExample)
CA (1) CA2286875A1 (enExample)
DE (1) DE69840165D1 (enExample)
ES (1) ES2314990T3 (enExample)
GB (2) GB9709421D0 (enExample)
HU (1) HUP0001931A3 (enExample)
IL (1) IL132348A0 (enExample)
MY (1) MY140975A (enExample)
NO (1) NO995475L (enExample)
NZ (1) NZ500014A (enExample)
PL (1) PL337007A1 (enExample)
RU (1) RU2218404C2 (enExample)
SK (1) SK153599A3 (enExample)
TR (1) TR199902731T2 (enExample)
WO (1) WO1998051787A2 (enExample)
ZA (1) ZA983931B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9910077D0 (en) * 1999-05-01 1999-06-30 Univ Manchester Chemical compounds
DE19946142A1 (de) 1999-09-27 2001-03-29 Bundesrepublik Deutschland Let Gentransfer in humane Lymphocyten mittels retroviraler scFv-Zelltargeting Vektoren
GB0001653D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Uk Ltd Chemical compound
GB0102239D0 (en) 2001-01-29 2001-03-14 Cancer Res Ventures Ltd Methods of chemical synthisis
WO2002094318A1 (en) * 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
US7244592B2 (en) 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
WO2003104425A2 (en) * 2002-06-07 2003-12-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Novel stable anti-cd22 antibodies
WO2004069269A1 (en) * 2003-01-30 2004-08-19 Neurologix, Inc. Method for making a cell more susceptible for a compound by expressing the protein, on which said compound acts, in said cell
PT2829283T (pt) 2003-04-30 2017-09-08 Univ Zuerich Método para tratamento do cancro utilizando uma imunotoxina
EP1691763A4 (en) * 2003-12-12 2008-03-12 Genencor Int MOLECULES CAB
US7910593B2 (en) 2004-04-09 2011-03-22 Chugai Seiyaku Kabushiki Kaisha Water-soluble prodrugs
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
WO2007071422A2 (en) * 2005-12-21 2007-06-28 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
WO2008128330A1 (en) * 2007-04-19 2008-10-30 Viventia Biotech Inc. Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins
CA2700815A1 (en) * 2007-09-27 2009-04-02 Viventia Biotech Inc. Optimized nucleic acid sequences for the expression of vb4-845
US8771679B2 (en) 2008-08-13 2014-07-08 The John Hopkins University Prodrug activation in cancer cells using molecular switches
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
CN104203982B (zh) * 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
JP6618360B2 (ja) 2012-08-03 2019-12-11 セダーズ−シナイ メディカル センター 薬物送達タンパク質の輸送向上変異体の単離
US9963515B2 (en) 2013-04-29 2018-05-08 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
PL3052525T3 (pl) 2013-10-02 2020-03-31 Viventia Bio Inc. Przeciwciała anty- EpCAM i sposoby wykorzystania
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
PE20170908A1 (es) 2014-10-29 2017-07-12 Teva Pharmaceuticals Australia Pty Ltd VARIANTES DE INTERFERON a2b
WO2016145349A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Methods of treatment for epcam positive bladder cancer
CA2979400A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Dosing strategies for targeting epcam positive bladder cancer
IL296662A (en) 2020-03-24 2022-11-01 Generation Bio Co Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
IL296660A (en) 2020-03-24 2022-11-01 Generation Bio Co Non-viral DNA vectors and their use for therapeutic expression of factor ix
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
WO2026085495A1 (en) 2024-10-18 2026-04-23 Generation Bio Co. Synthetic partially single-stranded nucleic acid compositions and uses and methods therefor
CN119454938B (zh) * 2024-11-15 2025-07-25 广州骐骥生物科技有限公司 一种枸橼酸透析浓缩液及其制备方法
CN119564851B (zh) * 2024-12-05 2025-08-22 广州骐骥生物科技有限公司 一种冰醋酸透析浓缩液及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB2276169A (en) * 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
DE4110409C2 (de) 1991-03-29 1999-05-27 Boehringer Ingelheim Int Neue Protein-Polykation-Konjugate
WO1993019163A1 (en) 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
GB9314960D0 (en) * 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds
WO1994006920A1 (en) 1992-09-22 1994-03-31 Medical Research Council Recombinant viruses displaying a nonviral polypeptide on their external surface
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
GB9323008D0 (en) 1993-11-05 1994-01-05 Connors Thomas Improvements relating to cancer therapy
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
GB9423367D0 (en) 1994-11-18 1995-01-11 Wellcome Found Enzyme prodrug therapy
CA2205091A1 (en) * 1994-12-23 1996-07-04 Zeneca Limited Chemical compounds
BR9610050A (pt) * 1995-08-16 1999-10-13 Zeneca Ltd Conjugado,sitemas de dois componentes combinados destinados a uso em um hospedeiro, compostos ou um sal destes famaceuticamente aceitavel,enzima,sequencia de polinucleotìdeos e de02 nucleotìdeos,vetor, célula hospedeira,processos de producão de uma enzima e de um conjugado e de tratamento de célulasneoplásticas em um hospedeiro,composicão farmaceutica e plasmìdeo
GB9523703D0 (en) 1995-11-20 1996-01-24 Wellcome Found Enzyme prodrug thearapy
GB9601640D0 (en) 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
BR9708910A (pt) * 1996-05-04 1999-08-03 Zeneca Ltd Anticorpo conjugado sequência de polinucleotídeos vetor célula hospedeira hibridoma composição farmacêutica processos para fabricar um anticorpo ou um conjugado e para tratar um humano ou animal em necessidade deste tratamento
PT1012259E (pt) 1997-06-04 2009-11-06 Oxford Biomedica Ltd Vector dirigido a tumor

Also Published As

Publication number Publication date
CN1268743C (zh) 2006-08-09
DE69840165D1 (de) 2008-12-11
RU2218404C2 (ru) 2003-12-10
ES2314990T3 (es) 2009-03-16
WO1998051787A2 (en) 1998-11-19
CN1255163A (zh) 2000-05-31
HUP0001931A2 (hu) 2000-09-28
MY140975A (en) 2010-02-12
EP0979292B1 (en) 2008-10-29
PL337007A1 (en) 2000-07-31
ATE412755T1 (de) 2008-11-15
GB2338484A (en) 1999-12-22
SK153599A3 (en) 2000-06-12
AU7225498A (en) 1998-12-08
ZA983931B (en) 1998-11-10
GB9922815D0 (en) 1999-11-24
AU734915B2 (en) 2001-06-28
IL132348A0 (en) 2001-03-19
KR100508136B1 (ko) 2005-08-10
NO995475L (no) 2000-01-07
HUP0001931A3 (en) 2003-10-28
US6339070B1 (en) 2002-01-15
NO995475D0 (no) 1999-11-09
CA2286875A1 (en) 1998-11-19
WO1998051787A3 (en) 1999-04-01
TR199902731T2 (xx) 2000-06-21
KR20010012441A (ko) 2001-02-15
JP2001526539A (ja) 2001-12-18
GB2338484B (en) 2001-11-07
NZ500014A (en) 2001-08-31
EP0979292A2 (en) 2000-02-16
BR9808769A (pt) 2000-08-01

Similar Documents

Publication Publication Date Title
PL337007A1 (en) Chemical compounds
EP1383864A4 (en) ISOPRENOIDPRODUKTION
AU2002225997A1 (en) Two chamber cell culture vessel
CA2315274A1 (en) Polypeptides having aminopeptidase activity and nucleic acids encoding same
AU7381098A (en) Polypeptides having prolyl pipeptidyl aminopeptidase activity and nucleic acids encoding same
IT1272179B (it) Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
WO2002016583A3 (en) Constructs and their use in metabolic pathway engineering
WO2002006457A3 (en) Novel lipase genes
AU3246300A (en) Polypeptides having galactose oxidase activity and nucleic acids encoding same
DE60043443D1 (de) Phytase enzyme, dafür kodierende nukleinsäuren, und solche enthaltende vectoren und wirtszellen
EP0919622A3 (en) Surface expression of enzyme in gene directed prodrug therapy
AU3644299A (en) A method for the targeting of proteins produced by (yersinia) into the cytosol of eukaryotic cells
AU5539898A (en) Nucleic acid construct for the cell cycle regulated expression of structural genes
AU2001278734A1 (en) Method of extensive culture of antigen-specific cytotoxic t cells
AU7489098A (en) Polypeptides having aminopeptidase activity and nucleic acids encoding same
AU2002243443A1 (en) Method and composition for inhibition of tumor growth and enhancing an immune response
NZ309171A (en) use of apoptin as an antitumour agent which specifically kills tumour and not normal cells
GB9825096D0 (en) Cells,culture methods and their uses
IL148360A0 (en) A herpes viral mutant and pharmaceutical compositions containing the same
WO1995030439A3 (en) Prevention of tumor metastasis
WO2001064912A3 (en) Triazine degrading enzymes
GB2379446A (en) Cells,culture methods and their uses
AU5515501A (en) Mammalian cell culture chamber
AU2001269863A1 (en) Targeting viral vectors to specific cells
AU2182801A (en) Method for producing adherent animal cells